First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study

PURPOSE: Combining bevacizumab with paclitaxel significantly improves progression-free survival (PFS) versus paclitaxel alone in HER2-negative metastatic breast cancer (MBC). Eribulin is active and tolerable in pretreated MBC. To assess whether eribulin may offer a more tolerable yet effective combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hardy-Bessard, Anne-Claire, Brocard, Fabien, Clatot, Florian, Lortholary, Alain, You, Benoît, Grenier, Julien, Martin-Babau, Jérôme, Lucas, Brigitte, Meunier, Jérôme, Ferrero, Jean-Marc, Savoye, Aude-Marie, Marti, Adina, Despax, Raymond, Moullet, Isabelle, Emile, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672314/
https://www.ncbi.nlm.nih.gov/pubmed/33188992
http://dx.doi.org/10.1016/j.breast.2020.09.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672314/
https://www.ncbi.nlm.nih.gov/pubmed/33188992
http://dx.doi.org/10.1016/j.breast.2020.09.011

Ejemplares similares